What Adenocard treats: main uses and benefits

Adenocard is a sterile solution containing adenosine, a substance that occurs naturally in all cells of the body. It is primarily used in clinical settings to manage specific heart rhythm disorders and to assist in diagnostic procedures related to cardiovascular health.

Conversion of Supraventricular Tachycardia

The primary therapeutic use of Adenocard is for the rapid conversion of paroxysmal supraventricular tachycardia (PSVT) to a normal sinus rhythm. PSVT is a condition characterized by a rapid heart rate that originates in the heart chambers above the ventricles.

Adenocard works by slowing the conduction time through the atrioventricular (AV) node. This action can interrupt the electrical reentry pathways that frequently cause these rapid heart rates, allowing the heart to reset to its natural rhythm. It is particularly effective for cases associated with Wolff-Parkinson-White Syndrome, where an abnormal extra electrical pathway exists between the upper and lower chambers of the heart.

Diagnostic Applications

Beyond its use in treating active rhythm disturbances, Adenocard serves as a diagnostic tool in specific medical scenarios:

• Identification of Heart Rhythms: Because the medication briefly slows electrical conduction, it can help healthcare professionals better visualize and identify the underlying rhythm of the heart when a patient is experiencing complex tachycardias.
• Myocardial Perfusion Imaging: Adenocard may be used during stress tests for patients who are unable to exercise adequately. By acting as a vasodilator, it increases blood flow through the coronary arteries, allowing for the assessment of blood flow to the heart muscle using imaging techniques.

Key Benefits

• Rapid Onset of Action: Adenocard acts very quickly upon administration, which is critical during acute episodes of rapid heart rate.
• Short Duration: The substance is cleared from the bloodstream within seconds, meaning its effects—and any associated sensations—typically resolve almost immediately after the procedure or treatment is complete.
• Natural Mechanism: As a synthetic version of a naturally occurring nucleoside, it utilizes the body's own biological pathways to regulate electrical activity in the heart.

Regulatory References

1. NIH DailyMed document on Adenosine Injection

Adenocard eligibility is defined by strict regulatory guidelines focusing on pre-existing cardiac conduction, pulmonary function, and reproductive status, as documented in official government labeling.

Populations Who Cannot Use Adenocard (Contraindications)

Use is absolutely prohibited for patients with:

• Second- or Third-Degree Atrioventricular (AV) Block or Sinus Node Disease (e.g., Sick Sinus Syndrome), unless a functioning artificial pacemaker is present.
• Known or Suspected Bronchoconstrictive or Bronchospastic Lung Disease (e.g., Asthma).
• Known Hypersensitivity to the active ingredient, adenosine.

Populations Requiring Conditional or Restricted Use

• Pre-existing Conduction Defects: Patients with First-Degree AV Block or Bundle Branch Block should receive the medicine with caution.
• Geriatric Patients (Aged 65 and Over): Use requires caution because controlled studies did not include sufficient numbers to establish differential response.
• Pediatric Use: Safety and efficacy have not been established in controlled clinical trials.
• Pregnancy and Lactation: Use is not recommended; it is only permitted during pregnancy (Category C) if the benefit is clearly judged to outweigh the potential fetal risk.
• Organ Function: Patients with hepatic or renal impairment are not restricted from standard use, as the drug's activity is independent of these organ systems.

Interactions with other medicines and products

Interaction Scope

Medicinal product categories with documented interactions:

• Methylxanthines (e.g., Theophylline, Aminophylline)
• Nucleoside Transport Inhibitors (e.g., Dipyridamole)
• Cardioactive Drugs affecting AV Nodal Function (e.g., Digoxin, Verapamil, Carbamazepine)

Specific interacting medicines (if explicitly listed):

• Dipyridamole
• Theophylline, Aminophylline
• Digoxin, Verapamil, Carbamazepine
• Xanthine-containing food and drinks (e.g., Coffee, Tea, Cola)

Mechanistic basis of interactions (only if stated in label):

• Competitive antagonism at the receptor (Methylxanthines).
• Inhibition of nucleoside transport (Dipyridamole).
• Additive depressant effects on the SA and AV nodes (Digoxin, Verapamil, Carbamazepine).

Timing-based interaction rules (if applicable):

• Dipyridamole must be stopped for at least 24 hours before administration.
• Methylxanthine medicines should be avoided for 24 hours prior to use.
• Xanthine-containing food and drinks should be avoided for at least 12 hours prior to use.

Population-specific interaction notes (if applicable):

• Geriatric Patients: Caution is advised due to possible concomitant drug therapies that may alter hemodynamic function and produce severe bradycardia or AV block.

Interaction-related restrictions:

• Dipyridamole is classified as a contraindicated combination or should not be administered, as it potentiates adenosine's effects.
• Methylxanthines are not recommended prior to use due to their antagonistic effect, which may reduce efficacy.

Interaction classifications (high-level):

• Potentiation/Toxicity Risk (Dipyridamole)
• Antagonism/Efficacy Reduction (Methylxanthines)
• Additive Conduction Depression (Digoxin, Verapamil, Carbamazepine)

Resulting interaction structure: Regulatory documentation defines the product's interaction structure around a high risk of potentiation due to transport inhibition (dipyridamole) and a risk of antagonism due to receptor competition (methylxanthines). Both require mandatory timing and avoidance rules. Official labels also note the potential for additive depressant effects when co-administered with other heart-rate modifying medicines.

Adenocard, which contains the active substance adenosine, acts endogenously as a purine nucleoside. Its primary biological target in cardiac tissue is the A1 (adenosine 1) receptor, a subtype of G-protein-coupled receptor. Adenosine binds to these A1 receptors located on the surface of atrial and nodal cells, particularly within the sinoatrial (SA) and atrioventricular (AV) nodes.

This binding event activates the inhibitory G protein ( G i), initiating a mechanistic cascade. G i protein activation modulates adenylate cyclase activity, leading to a decrease in the intracellular concentration of cyclic adenosine monophosphate (cAMP). Furthermore, the activated G i protein directly facilitates the opening of specific inwardly rectifying potassium channels ( I K,Ado) and reduces calcium influx by inhibiting L-type calcium channels. This resulting hyperpolarization and reduced calcium entry decreases the automaticity of the SA node and prolongs the effective refractory period of the AV node, thereby altering the electrical conduction properties within the heart's specialized tissues.

Instruction Map: How to use Adenocard — Administration Guidelines

Administration Scope

Route of administration: Intravenous (IV) Injection only.

Dosing schedule:

• Acute Rhythm Conversion (Adults): Dosing regimens vary. A common regimen starts with a 6 mg rapid IV bolus, followed by up to two additional 12 mg boluses separated by 1–2 minutes, if required. In some clinical contexts, the ascending schedule may begin at 3 mg, followed by 6 mg, then 12 mg.
• Diagnostic Cardiac Stress Testing (Adults): Administered as a continuous peripheral IV infusion at a standardized rate of 0.14 mg/kg/minute for a duration of 6 minutes.

Timing in relation to meals (if applicable): Not applicable; administration is acute intravenous.

Preparation requirements (if applicable): Must be visually inspected for discoloration or particulate matter prior to use; the solution must not be administered if either is present.

Age-group administration rules:

• Pediatric Patients (<50 kg): Dosing for acute conversion is calculated on a weight basis, beginning with a lower mg/kg rapid IV bolus dose and titrating up as needed.

Missed-dose rules: Not applicable; this is an acute or procedural medication, not a maintenance drug.

Special procedural conditions:

• If administered via a central venous line, the initial acute dose is typically reduced to 3 mg.

Instruction Classifications (High-Level)

Administration method type: Parenteral (IV Bolus / Infusion).

Frequency pattern: Acute, single-event use or Fixed-duration procedure.

Use-context constraints: Use is restricted to a supervised clinical setting with appropriate monitoring and equipment.

Resulting Procedural Structure

Step sequence:

• Administer the dose as a rapid IV bolus push over 1–2 seconds.
• Immediately follow the injection with a rapid saline flush (e.g., 20 mL).
• The injection should be made into a vein located as proximally as possible.

Connection to the overall use protocol: Standardized protocols define a rigid, time-sensitive sequence for Adenocard use, mandating an intravenous route with a highly specific rapid bolus technique and a defined dose titration schedule for acute management. This structured approach, which includes fixed doses and mandatory clinical supervision, standardizes the delivery of the drug within the controlled procedural context. The entire use profile is characterized by acute or procedural management, strictly defined by dose, technique, and timing.

Research evidence / Overview of Studies for Adenocard

Evidence for Use in Acute Conversion of Supraventricular Tachycardia (SVT)

Research exploring the use of adenosine for acute management of rapid heart rhythms, specifically Paroxysmal Supraventricular Tachycardia (PSVT), has primarily involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been conducted in controlled clinical environments, examining patients experiencing acute, episodic changes in heart rhythm. The key outcome that researchers monitored was the immediate occurrence of normal sinus rhythm conversion following rapid intravenous administration. The evidence includes trials where the medication was evaluated against an inactive agent and against other antiarrhythmic agents.

The studies describe patterns related to the time taken for a change in heart rhythm to occur, indicating that any measurable effect is very brief due to the fast nature of the physiological response observed. Findings from the RCTs describe the characteristics of the administration procedure in the context of the observed physiological response. The evidence contributes to understanding symptom patterns in patients with conditions characterized by acute or disruptive episodes.

---

Evidence for Use in Pharmacological Stress Testing

Adenocard was evaluated in numerous diagnostic accuracy studies and comparative imaging trials for its role as a pharmacological agent studied to simulate the effects of exercise. This is primarily relevant for patients who are unable to physically exert themselves for a standard treadmill test. These studies focused on patient populations with certain physical limitations or pre-existing cardiac rhythm issues (such as Left Bundle Branch Block) that may complicate exercise testing.

---

Long-Term Follow-up and Durability of Evidence

The body of research focuses heavily on the acute and immediate effects of adenosine, which aligns with the immediate, temporary nature of the physiological response observed in the research. For the treatment of PSVT, the follow-up durations in the primary conversion trials were typically limited to the immediate post-administration period. Consequently, there is limited information available regarding the long-term stability of the heart rhythm or the durability of response many weeks or months after the acute episode.

---

Key Evidence Gaps and Areas of Uncertainty

While there is high-level evidence supporting the acute and diagnostic uses of Adenocard, several research limitations exist. The short duration of follow-up in most core efficacy studies means that data for sustained, long-term results remain insufficient. Furthermore, findings for certain subgroups, particularly those with complex or rare pre-existing heart conditions, may be heterogenous or based on smaller sample sizes, meaning evidence quality varies across studies for these groups. Research is ongoing to help contextualize how patients reported their experience and to describe observed patterns in different scenarios.

Key Studies & References

1. Label: ADENOSINE injection - DailyMed (NIH/NLM)
2. ASNC Practice Point: Pharmacologic Stress Testing – Adenosine
3. Adenosine vs. Regadenoson in Cardiac Stress Testing - American College of Cardiology
4. Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended ADENOSINE (EMA/National Agency Review)
5. Optimal Dose of Adenosine Effective for Supraventricular Tachycardia in Children

Common questions about Adenocard (FAQ)

Q: How quickly does Adenocard start to work?

According to official product information, adenosine is known for its extremely fast action. Intravenously administered adenosine is rapidly cleared from the circulation with a half-life of less than 10 seconds in the bloodstream. Clinical studies describe that the heart rhythm of patients with the target condition often returns to normal sinus rhythm within approximately one minute of administration.

---

Q: How long does the effect of Adenocard last in the body?

The drug’s effects are designed to be extremely short-lived, or transient. Regulatory sources state that adenosine is cleared from the plasma in less than 30 seconds, with a half-life of under 10 seconds. This rapid breakdown and clearance from the body is why the medication’s effects are observed to resolve very quickly after it is administered.

---

Q: What is the difference between Adenocard and Adenoscan?

Both Adenocard and Adenoscan are brand names for the same active substance: adenosine injection. The different brand names are commonly associated with the two main therapeutic uses of the medication: Adenocard for rapid conversion of fast heart rhythms, and Adenoscan for its use as a cardiac stress agent.

---

Q: Why do some people feel a short period of breathlessness after receiving Adenocard?

Official safety documents list dyspnea (shortness of breath) or an urge to breathe deeply as a very common reaction. This effect is part of the drug's immediate impact on the body, but as with most effects of the drug, this sensation is generally transient (short-lived) and is observed to resolve rapidly.

---

Q: Does Adenocard make you feel a strange sensation in your chest?

Official reports indicate that it can. Clinical trials list chest discomfort or pain as a very common adverse reaction following administration. As with other reported effects, this sensation is generally observed to be transient (short-lived).

---

Q: Can Adenocard cause flushing or redness of the face?

Regulatory documents indicate that it can. Flushing—described as a feeling of warmth, redness, or tingling of the skin—is the most frequent adverse reaction reported in clinical trials. It is observed in a large percentage of patients, but is generally described as transient.

---

Q: Is it true that caffeine should be avoided before receiving Adenocard?

Official drug labels describe that xanthine-containing food and drinks, including coffee and other caffeinated beverages, should be avoided for at least 12 hours prior to administration. This is because substances like caffeine are methylxanthines that can antagonize (reduce the effectiveness of) adenosine.

---

Q: Why do doctors check my heart rhythm before and after giving the drug?

Official administration instructions require that the medicine be used only in a controlled clinical environment with continuous electrocardiographic (ECG) monitoring. This is required to observe the drug's intended action of slowing conduction through the heart's electrical system, and to identify any changes in heart rhythm that may occur.

---

Q: Why does the heart speed up before it slows down when Adenocard is given?

The primary goal of the medication is to slow conduction through a specific part of the heart's electrical system, but official documentation notes that transient and short-lived arrhythmias can occur following administration. These may include sinus tachycardia (a temporarily fast heartbeat) before the primary, desired effect of rhythm conversion takes place.

---

Q: Does using tobacco products affect how Adenocard works?

The official label specifies an interaction with methylxanthines (such as caffeine), which are substances chemically related to the drug. Some authoritative medical sources note that nicotine, which is found in tobacco products, may also act as an antagonist (reducing agent) to adenosine’s effects.

---

Q: What is the general expectation for how a patient feels immediately after treatment?

Because the side effects are rapid-onset and transient, the general feeling immediately following the injection often includes a quick rush of sensations such as flushing, a sense of chest discomfort, shortness of breath, and headache. These sensations are commonly observed to resolve quickly due to the drug's ultra-short duration of action.

---

Q: Does Adenocard stop heart rhythm problems permanently?

Official sources state that Adenocard is indicated for the acute termination (rapid stop) of specific fast heart rhythms. The drug’s function is designed for immediate, acute effect and is not described in research as a permanent or long-term cure for heart rhythm problems.

---

Q: Is Adenocard considered a 'blood pressure' drug?

No. The drug’s official classification is an antiarrhythmic agent and a pharmacological stress agent; it is not classified as a blood pressure drug. However, adenosine is known to cause a transient hypotension (temporary low blood pressure) and is a potent peripheral vasodilator (widens blood vessels), which can occur as a side effect.

---

Q: Can Adenocard be used for all types of fast heart rhythms?

No. Official labeling clearly indicates that the drug is approved only for the acute termination of Paroxysmal Supraventricular Tachycardia (PSVT). The drug does not convert other common rhythms, such as atrial flutter, atrial fibrillation, or ventricular tachycardia, to a normal sinus rhythm.

---

Q: Can receiving Adenocard make me dizzy or lightheaded?

Regulatory documents state that it can. Dizziness and lightheadedness are listed as common adverse reactions in clinical trials documented in regulatory sources. Like the other adverse effects, these sensations are typically transient (short-lived) because the drug is cleared from the body very rapidly.

---

Q: Are there any long-term side effects associated with Adenocard?

Official safety documents focus on effects that are rapid-onset and transient due to the drug’s extremely short half-life and rapid clearance from the body. Consequently, the medicine is not typically associated with chronic or long-term side effects.

---

Q: Is Adenocard safe for use in children?

Controlled clinical trials have not established the medication’s safety and effectiveness for pediatric patients. However, some regulatory bodies have provided specific weight-based dosing guidelines for use in children, suggesting its use is reserved for specific, monitored contexts.

---

Q: What happens if someone has a known allergy to Adenocard?

A known hypersensitivity or allergy to adenosine is listed as an absolute contraindication in official product information. This means that according to official guidelines, the medication is not to be administered to an individual with a known allergy.

---

Q: What does it mean if the treatment with Adenocard doesn't work the first time?

If the initial dose fails to convert the heart rhythm, official dosing protocols allow for the administration of up to two additional, increasing bolus doses within minutes of the first. The allowance for additional doses is part of the structured protocol described in official prescribing information.

---

Q: Does Adenocard affect the normal electrical system of the heart?

Yes, it does. Adenosine works by creating a transient depressant effect on the heart's sinoatrial (SA) and atrioventricular (AV) nodes, which are critical parts of the heart's normal electrical conduction system. This is the physiological mechanism by which the drug achieves its desired rhythm-slowing effect.

---

Q: Is it possible to receive Adenocard more than once in a short period?

Yes. The official dosing regimen for acute rhythm conversion explicitly allows for two subsequent doses to be administered within minutes of the initial dose if the first dose is unsuccessful at converting the rhythm.

---

Q: Why is the drug sometimes used as part of a stress test?

The drug is indicated for use as a pharmacologic stress agent for cardiac imaging, which is an alternative to physical exercise. It works by causing a rapid vasodilation (widening) of the arteries in the heart, simulating the effects of physical exertion for diagnostic purposes.

---

Q: Do women who are pregnant or breastfeeding typically receive Adenocard?

Official documents state that use during pregnancy is not recommended unless the potential benefit is clearly judged to outweigh the potential fetal risk. For breastfeeding, it is not known if adenosine is excreted in human breast milk, and caution is advised for its use during this time.

---

Q: Is Adenocard typically painful when administered?

Official safety documents list the common adverse reaction of chest discomfort or pain, but do not specifically list pain at the injection site or related to the administration procedure as a common adverse reaction.

---

Q: Can someone drive or operate machinery soon after receiving Adenocard?

The drug can cause common side effects such as dizziness or lightheadedness. Because of these transient effects and the need for clinical monitoring, guidelines generally state that patients should avoid driving or operating machinery immediately following the procedure.

---

Q: Why might a patient need to fast or follow diet instructions before the procedure?

Dietary instructions, such as avoiding xanthine-containing foods and drinks like caffeine for at least 12 hours prior, are required. This is because these substances are known to antagonize (reduce the effectiveness of) the medication.

Official Storage and Disposal Requirements

Adenocard (adenosine injection) must be stored at Controlled Room Temperature, which is defined as 20 to 25 C (68 to 77 F). The solution must not be refrigerated, as this can lead to crystallization. If crystals form, the vial should be warmed to room temperature until the solution becomes clear. The medicine must be visually inspected and must be clear at the time of use.

Because the solution contains no preservative, regulatory labeling mandates that any unused portion remaining in the vial must be discarded immediately after administration. General disposal guidelines recommend discarding unused medicines in the household trash after mixing with an unappealing substance, or by utilizing authorized medicine take-back programs.